Overview

Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors

Status:
Terminated
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this open-label, multi center, phase I study, was to determine the safety profile of PHA-793887 administered by intravenous infusion to patients with advanced/metastatic solid tumors. This was a dose-finding study to determine the maximum tolerated dose and the dose of PHA-793887 that can be safely used in phase II investigations.
Phase:
Phase 1
Details
Lead Sponsor:
Nerviano Medical Sciences